環丙西泮
 | |
 | |
| 臨床資料 | |
|---|---|
| 給藥途徑 | 口服 |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 藥物代謝 | Hepatic |
| 排泄途徑 | Renal |
| 識別資訊 | |
| |
| CAS號 | 15687-07-7  |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| 化學資訊 | |
| 化學式 | C19H18ClN3O |
| 摩爾質量 | 339.82 g·mol−1 |
| 3D模型（JSmol） | |
| |
| |
環丙西泮（英語：Cyprazepam[1]）是一種鎮靜催眠苯二氮䓬衍生物藥物。[2][3][4][5]它具有抗焦慮特性，[6]並且可能還具有催眠、骨骼肌鬆弛、抗驚厥和遺忘特性。
合成[編輯]
苯二氮䓬類藥物中的內酰胺部分對親核試劑具有活性，並且利用這一事實製備了許多類似物。
例如，將地莫西泮與N-環丙基甲胺加熱會形成脒，即次要鎮靜劑環丙西泮。
參見[編輯]
參考資料[編輯]
- ^ 1.0 1.1 US 3138586,Wuest HM,「2-Cycloalkylamino Derivatives of 1,4-Benzodiazipines」,發行於23 June 1964,指定於Warner-Lambert Pharmaceutical Compay; Chem. Abstr., 61: 7,032f (1964).
- ^ Oelschläger H, Martienssen D, Belal F. Ring Contraction of 1,4-Benzodiazepines to 3,4-Dihydroquinazolines During Macro Scale Reduction (Example 5: Cyprazepam). Archiv der Pharmazie (Wiley Interscience). 22 September 2006, 325 (8): 503–507. ISSN 0365-6233. S2CID 96638676. doi:10.1002/ardp.19923250810. （原始內容存檔於5 January 2013）.
- ^ EP 1466628,Matthews B, Victor S, Nigel, Swindell C,「DHA-pharmaceutical agent conjugates」,發表於13 October 2004,指定於American Regent Inc. （頁面存檔備份，存於互聯網檔案館）
- ^ Harmonized Tariff Schedule of the United States (2009) - Supplement 1 - PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE (PDF). USA: United States International Trade Commission. 2009 [19 September 2009]. （原始內容 (PDF)存檔於31 July 2009）.
- ^ Schafer EW, Bowles WA, Hurlbut J. The acute oral toxicity, repellency, and hazard potential of 998 chemicals to one or more species of wild and domestic birds. Archives of Environmental Contamination and Toxicology. May 1983, 12 (3): 355–82. Bibcode:1983ArECT..12..355S. PMID 6882015. S2CID 32956594. doi:10.1007/BF01059413.
- ^ World Health Organization. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (PDF). USA: Ministry of health, Syria. 2006 [19 September 2009]. [失效連結]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||